MUC1 and cancer: When treated with Apt-Td-Dox, significantly more doxorubicin was observed in the MUC1-positive cancer cells compared with the MUC1-negative control cells (Figure 5A lower panel), indicating that a targeted-delivery of doxorubicin occurred in vitro.